Organization
Department of Hematology, The First Hospital of China Medical University, Shenyang, China
2 abstracts
Abstract
Latest results of a phase 2 study of IMM01 combined with azacitidine (AZA) as the first-line treatment in adults with higher risk myelodysplastic syndromes (MDS).Org: Shengjing Hospital Affiliated to China Medical University, Shenyang, China, Department of Hematology, The First Hospital of China Medical University, Shenyang, China, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, China, Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China, Shanghai Sixth People's Hospital, Shanghai, China,
Abstract
Health-related quality of life and economic burden in Chinese patients with cutaneous T-cell lymphoma.Org: Happy Life Tech Co., Ltd, Kyowa Kirin China Pharmaceutical, Department of Dermatology, Peking University First Hospital, Beijing, China, Department of Dermatology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College, Nanjing, China, Department of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China,